SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports suggesting that GameStop may be preparing a takeover offer for the e-commerce giant, sparking intense debate among investors regarding the feasibility and logic of such a merger. The community is actively discussing the massive valuation gap, potential financing obstacles, and whether this narrative is a genuine strategic pivot or a speculative-driven market event.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

The community is rallying behind the token's identity as the original AI dog associated with Grok, highlighting its unique lore and recent exchange listing as key catalysts. Enthusiasts are actively discussing the ticker's long-term potential in the AI-meme sector, often emphasizing the project's deflationary mechanics and organic, community-driven growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as a segment of the community remains highly bullish, pointing toward active token burns, anticipated ecosystem project launches, and potential long-term price recovery. While some investors advocate for holding in hopes of a major supply shock, others are actively debating the token's future utility and the historical context of its market performance.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as speculators aggressively debate the potential for massive percentage gains while others warn of volatility and compare the asset to other community-driven meme projects. The community remains hyper-focused on monitoring volume, navigating whale activity, and looking for signs of upward momentum.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is trending following positive Phase 3 clinical data for its cancer treatment Ziihera, which has sparked significant discussion regarding the drug's potential to become a new standard of care in oncology. Community sentiment remains focused on the company's long-term pipeline potential and its ability to secure M&A interest from larger industry players.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing significant community momentum and social buzz, with investors actively discussing potential exchange listings and the goal of shedding multiple zeros from its price. While some market participants raise concerns about its large supply and historical performance, the community remains focused on potential breakout growth driven by upcoming network utility and broader altcoin market recovery.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is seeing significant investor attention driven by a record-high funded backlog and a series of strategic contracts in satellite and quantum sensing technologies. The community is actively discussing the stock's potential for long-term growth as it pivots to next-generation defense applications while maintaining a debt-free balance sheet.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is gaining traction as community members highlight its role as a core DEX on Solana, driving excitement around the project's ecosystem integration and active trading environment. Discussion is further fueled by the ongoing presence of community-led memecoin initiatives like $UPDOG, which leverage Jupiter's strict list to maintain visibility and engagement.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is currently generating intense community debate as traders split between bullish optimism over potential real-world asset integration and bearish warnings from skeptics who view recent price action as a classic pump-and-dump trap. The conversation remains highly polarized, with active discussion focusing on the token's long-term utility versus its history of volatility and increasing circulating supply.

Daddy Darth Vader

Daddy Darth Vader is trending as investors debate the project's future amidst intense community rivalries, with many participants speculating on potential market activity and comparing it to other memecoins. Holders are actively discussing strategies to push the token forward, emphasizing community-driven growth and upcoming milestones to sustain momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arvinas (NASDAQ:ARVN) Shares Up 9.9%  - What's Next?

Arvinas (NASDAQ:ARVN) Shares Up 9.9% - Time to Buy...

<ul class="summary-bullets"><li>The decision also marks the FDA’s first approval of a PROTAC therapy, a type of targeted protein-degrading drug.</li><li>The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease progression or death by 43% compared with Fulvestrant.</li><li>Arvinas and Pfizer plan to partner with a third party to support the drug’s commercial rollout.</li></ul>Shares of Arvinas Inc. (ARVN) gained nearly 10% on Friday, after the company announced that the U.S. Food and Drug Administration approved its breast cancer drug to treat patients with ES1 mutations.The drug, Vepdegestrant, which will be marketed as Veppanu, was jointly developed with Pfizer (PFE). The approval comes more than a month ahead of the Prescription Drug User Fee Act (PDUFA) action date.The decision also marks the FDA’s first approval of a Proteolysis Targeting Chimera (PROTAC) therapy, a type of targeted protein-degrading drug.<h2 class="st-heading-2">Disease Progression Reduced By 43%</h2>The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease progression or death by 43% compared with Fulvestrant, an injection for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Median progression-free survival improved to five months versus 2.1 months.Arvinas and Pfizer plan to partner with a third party to support the drug’s commercial rollout.“We are especially encouraged by receiving FDA approval ahead of the June 5 PDUFA date, and together with Pfizer, we are on track to announce selection of a third party to bring this new treatment option to patients as soon as possible,” said Randy Teel, President and CEO at Arvinas.The drug received Fast Track designation from the FDA in 2024, followed by the agency’s acceptance of its New Drug Application (NDA) for review last August.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ARVN">ARVN</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.One user sees the stock as a “long-term hold.”<stembedurl>https://stocktwits.com/Regulator06/message/652035353</stembedurl>The stock has declined 11% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sobr-stock-merger-/cZQVaFFReeS">This Nanocap Stock Surged More Than 100% After A Strategic Pivot To Tap Into AI Data Center Market – Retail Bulls See Bigger Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arvinas logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule

The FDA approved Veppanu on Friday, which was jointly developed by Pfizer and the company.

Equity

Arvinas (ARVN) Expected to Announce Earnings on Thursday

Arvinas (NASDAQ:ARVN) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-arvinas-inc-stock...

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been given an average rating of "Hold" by the nineteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts...

JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN

JPMorgan Chase & Co. lifted its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 475.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,779 shares of the company's stock after buying an additional 1...

Arvinas (NASDAQ:ARVN)  Shares Down 5.1%   - Time to Sell?

Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Should You Sell...

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been assigned an average recommendation of "Hold" from the nineteen research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have assigned...

Arvinas (NASDAQ:ARVN) Insider Sells $71,428.50 in Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Noah Berkowitz sold 6,435 shares of the business's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of...

Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Noah Berkowitz sold 6,435 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $11.10, for a total value of $71,428.50. Following the transaction, the insider owned 202,503 shares...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.92	--	--	N/A
Q4 '25	-$0.56	-$1.10	-95.76%	MISSED
Q3 '25	-$0.71	-$0.48	32.10%	BEAT
Q2 '25	-$0.94	-$0.84	10.17%	BEAT
Q1 '25	-$0.96	$1.14	218.15%	BEAT

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ARVN News

ARVNArvinas Inc